Flosonics Medical secures $20m in Series C for wearable medical ultrasound technology

Flosonics Medical, a forefront innovator in wearable medical ultrasound technology, has successfully completed its Series C financing round, raising an impressive $20 million USD. This milestone funding round was led by New Leaf Venture Partners, a prominent figure in healthcare technology venture investing, with significant contributions from existing investors including Arboretum Ventures, Genesys Capital, and iGan Partners. This new influx of capital is earmarked for bolstering the market adoption and ongoing innovation of the FloPatch, Flosonics Medical’s flagship product and a first-of-its-kind wearable Doppler ultrasound device designed for hemodynamic assessments.

The funding round also ushers in a new phase of leadership with the addition of Vijay Lathi, a seasoned MedTech investor known for his expertise in data convergence and guiding growth-stage companies, to Flosonics Medical’s board of directors. “We are thrilled to have New Leaf Venture Partners lead our Series C round and welcome Vijay Lathi to our board,” expressed Joe Eibl, CEO of Flosonics Medical. Eibl’s statement underscores the strategic significance of this funding, which is poised to accelerate the company’s expansion plans and innovation pathways. It also reflects the company’s commitment to enhancing care standards for critically ill patients through the FloPatch and expanding its market presence.

Vijay Lathi, representing New Leaf Venture Partners, shared his enthusiasm about joining forces with Flosonics Medical. He emphasized the transformative potential of Flosonics’ technology in critical patient care situations and praised the quality of the team steering the company. This partnership is expected to catalyze further success and advancements in wearable ultrasound technology.

With the Series C investment, Flosonics Medical is set to accelerate its commercial growth, broaden the indications for the use of its technology, and continue its pursuit of evidence generation. The company’s vision aligns with the growing demand for wearable AI-assisted sensors that enhance patient management both within hospital settings and in broader healthcare environments. Founded in 2015, Flosonics Medical’s mission is centered on leveraging technology-enabled solutions and pioneering clinical research to improve patient care and the practice of medicine.

New Leaf Venture Partners, with a legacy of healthcare technology venture investing and managing over $500 million in assets, brings a wealth of experience and resources to this partnership. The collaboration between Flosonics Medical and New Leaf Venture Partners is a testament to the potential of innovative solutions in transforming healthcare and patient outcomes.